Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: A review

AIDS Reviews

Volumn 5, Issue 2, 2003, Pages 80-86

  Lafeuillade, Alain ^a   Tardy, Jean Claude ^b  

^a Hopital Chalucet Toulon   (France)

^b Rockefeller Medicine University   (France)

Author keywords

Cross resistance; Genotype; Nucleoside analogue mutations; Phenotype; Stavudine; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANALYTICAL EQUIPMENT; CLINICAL TRIAL; CODON; CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG USE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIMARY HEALTH CARE; REVIEW; TREATMENT PLANNING; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; STAVUDINE;

EID: 0037961209     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Pallela F, Delanay K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Deeks S, Hecht F, Swanson M, et al. HIV-1 RNA and CD4 cell count response to PI therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:35-43.
3. Miller M, Margot N, Lu B. Effect of baseline nucleoside-associated resistance on response to Tenofovir DF (TDF) therapy: Integrated analyses of studies 902 and 907. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 43].
4. Soriano V, De Mendoza C. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin Trials 2002;3:237-48.
5. Loveday C. Nucleoside reverse transcriptase inhibitors resistance. J Acquired Immune Defic Syndr 2001;26(Suppl):10-24.
6. Meyer P, Matsuura S, Mian A, So A, Scott W. A mechanism of AZT resistance: An increase in nucleotide-dependant primer unblocking by mutant HIV-1 RT. Mol Cell 1999;4:35-43.
7. Schmidt B, Korn K, Walter H. Technologies for measuring HIV-1 drug resistance. HIV Clin Trials 2002;3:227-36.
8. Wensing AM, Keulen W, Buimer M, et al. Analysis of the worldwide evaluation study on HIV-1 genotype interpretation; ENVA-3. Antiviral Ther 2001;6(Suppl 1):101.
9. Tural C, Ruiz L, Holter C, et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16:208-18.
10. Demeter L, Haubrich R. Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations. J Acquired Immune Defic Syndr 2001;26(Suppl):3-9.
11. Hertogs K, De Bethume M, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant immuno-deficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-76.
12. Petropoulos C, Parkin N, Limoli K, et al. A novel phenotypic drug susceptibility assay for HIV type 1. Antimicrob Agents Chemother 2000;44:920-8.
13. Race E, Dam E, Obry V, Paulous S, Clavel C. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13:2061-8.
14. Miller V, Schuurman R, Clavel F, et al. Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories. Antiviral Ther 2001;6(Suppl 1):129.
15. Larder B. Mechanisms of HIV-1 drug resistance. AIDS 2001;15(Suppl 5):27-34.
16. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-36.
17. Call S, Saag M, Westfall A, et al. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with HIV infection. J Infect Dis 2002;183:401-8.
18. Cohen C, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-88.
19. Lacey S, Larder B. Novel mutation (V75T) in HIV type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994;38:1428-32.
20. Lin P, Samanta H, Rose R, et al. Genotypic and phenotypic analysis of HIV type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170:1157-64.
21. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997;11:696-7.
22. Pellegrin I, Izopet J, Reynes A, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. AIDS 1999;13:1705-9.
23. Coakley E, Gillis J, Hammer S. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000;14:9-15.
24. De Mendoza C, Soriano V, Briones C, et al. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquired Immune Defic Syndr 2000;23:279-80.
25. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease genes in HIV type 1-infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999; 37:4099-106.
26. Larder B, Bloor S. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance. Antiviral Ther 2001;6(Suppl 1):38.
27. Harrigan P, Larder B. Extent of cross-resistance between agent used to treat HIV type 1 infection in clinically derived isolates. Antimicrob Agents Chemother 2002;46:909-12.
28. Whitcomb J, Paxinos E, Huang W, et al. The presence of nucleoside analogue mutations (NAMs) is highly correlated with reduced susceptibility to all NRTIs. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 569-T].
29. Lennerstrand J, Stammers D, Larder B. Biochemical mechanism of HIV type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 2001;45:2144-6.
30. Trouplin V, Mammano F, Clavel F. Why does stavudine select zidovudine resistance mutations? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 471].
31. Spruance S, Pavia A, Mellors J, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Ann Intern Med 1997;126:355-63.
32. Gallant J, Chaisson R, Keruly C, Moore R. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naïve patients. AIDS 1999;13:225-9.
33. Shulman N, Machenkano R, Shafer R, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquired Immune Defic Syndr 2001;27:377-80.
34. Becker S, Raffanti S, Hansen N, et al. Zidovudine and stavudine sequencing in HIV treatment planning: Findings from the CHORUS HIV cohort. J Acquired Immune Defic Syndr 2001;26:72-81.
35. Mouroux M, Descamps D, Izopet J, et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus lamivudine combination therapy. Antiviral Ther 2001;6:179-83.
36. Johnson V, Bassett R, Koel J, et al. Selection of zidovudine resistance mutations by zidovudine or stavudine-based regimens and relationship to subsequent virological response in ACTG 370. Antiviral Ther 2001;5(Suppl 3):42.
37. O'Brien W, Borucki M, Telleria L, et al. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 253].
38. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 448].
39. Lefebvre E, Thomas R, Machouf N, Lapointe J. Prevalence of mutations to reverse transcriptase enzyme in a zidovudine-naïve population experiencing virological failure. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 606].
40. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naïve patients experiencing viremia on stavudine-containing regimens. AIDS Research Human Retroviruses 2001;17:1107-15.
41. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16:1686-9.
42. Moyle G, Gazzard B. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. AIDS 2001;15:799-800.
43. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antiviral Ther 2002;7:211-8.
44. Moreno S, Casado JL, Pérez-Eleas MJ, et al. Development of resistance to stavudine (d4T) in patients who fail on d4T-containing regimens. 13th International AIDS Conference. Durban, July 2000 [abstract ThPpB1434].
45. Obry V, Costagliola D, Race E, et al. The extent of association between resistance phenotype and treatment response is highly dependant upon the drug. Antiviral Ther 2001;6(Suppl 1):61.
46. Lafeuillade A, Poggi C, Hittinger G, Chadapaud S. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Clin Trials 2001;2:231-5.
47. Soriano V. Sequencing antiretroviral drugs. AIDS 2001;15:547-51.
48. Keiser P. Role of sequencing in therapy selection. J Acquired Immune Defic Syndr 2002;29(Suppl 1):19-27.
49. Molina JM, Chene G, Ferchal F, et al. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with HIV. J Infect Dis 1999;180:351-8.
50. Squires K, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: Selection of thymidine analog regimen therapy (START I). AIDS 2000;14:1591-600.